FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099982247> ?p ?o ?g. }

• W2099982247 endingPage "481" @default.
• W2099982247 startingPage "476" @default.
• W2099982247 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Aug 2001INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL ADRIAN P.M. VAN DER MEIJDEN, MAURIZIO BRAUSI, VICTOR ZAMBON, WIM KIRKELS, CHRISTINE DE BALINCOURT, RICHARD SYLVESTER, and MEMBERS OF THE EORTC GENITO-URINARY GROUP* ADRIAN P.M. VAN DER MEIJDENADRIAN P.M. VAN DER MEIJDEN More articles by this author , MAURIZIO BRAUSIMAURIZIO BRAUSI More articles by this author , VICTOR ZAMBONVICTOR ZAMBON More articles by this author , WIM KIRKELSWIM KIRKELS More articles by this author , CHRISTINE DE BALINCOURTCHRISTINE DE BALINCOURT More articles by this author , RICHARD SYLVESTERRICHARD SYLVESTER More articles by this author , and MEMBERS OF THE EORTC GENITO-URINARY GROUP* Participants: A. van der Meijden, s’Hertogenbosch, C. Boeken-Kruger and W. Kirkels, Rotterdam, P. Karthaus and K. Kurth, Amsterdam, P. Vegt, Leiderdorp, J.-V. Zambon, Maastricht, The Netherlands; W. Oosterlinck, Gent, Belgium; J. Carballido, Madrid, Spain; P. Whelan, Leeds, R. Hall, Newcastle-upon-Tyne, D. Hanbury, Stevenage, United Kingdom; S. Ferretti, Carpi, A. Bono, Varese, G. Casetta, Torino, M. Brausi, Modena, Italy; F. Calais da Silva, Lisbon, Portugal; W. Hoeltl, Vienna, D. Mack, Salzburg, Austria; and Z. Kirkali, Izmir, Turkey. More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65966-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: After transurethral resection, we compared the efficacy and side effects of weekly intravesical instillations of epirubicin, bacillus Calmette-Guerin (BCG), and BCG plus isoniazid during a 6-week interval followed by 3 weekly maintenance instillations at months 3, 6, 12, 18, 24, 30 and 36 in patients with intermediate and high risk Ta, T1 bladder cancer. Materials and Methods: A total of 957 patients were randomized at 44 institutions in a phase III multicenter trial. Results: The time to first recurrence was significantly longer in patients treated with BCG and BCG plus isoniazid compared to epirubicin (p = 0.0001) but there was no difference between the 2 BCG regimens (p = 0.27). Progression to muscle invasive cancer was rare (5%) and did not differ significantly among the 3 arms (p = 0.12). Drug induced cystitis was observed in 31% of the patients treated with epirubicin, 42% BCG and 45% BCG plus isoniazid. Systemic side effects, such as fever and malaise, were not observed in patients treated with epirubicin, but were noted in 31% BCG and 36% BCG plus isoniazid. Conclusions: Intravesical BCG with or without isoniazid provokes more side effects than epirubicin. Prophylactic isoniazid does not reduce the side effects of BCG, while BCG with or without isoniazid prolongs the time to first recurrence compared to epirubicin. Further followup is required before long-term conclusions can be made for progression-to-muscle invasive disease and survival. References 1 : Prognostic factors in superficial bladder tumors. Prob Urol1992; 6: 471. Google Scholar 2 : A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol1993; 149: 749. Link, Google Scholar 3 : Effect of intravesical Mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J1988; 296: 1759. Google Scholar 4 : Bacillus Calmette-Guérin in superficial bladder cancer: consensus and controversies. Eur Urol1995; 27: 89. Google Scholar 5 : A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med1991; 325: 1205. Google Scholar 6 : Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol2000; 163: 1124. Link, Google Scholar 7 : Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses?. Int J Urol1995; 2: 23. Google Scholar 8 : Is intravesical BCG superior to chemotherapy?. In: Renal, Bladder and Prostate Cancer, an Update. Edited by . New York: The Parthenon Publishing Group1999: 227. Google Scholar 9 : Long term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and Mitomycin C in superficial bladder cancer. Urology1998; 52: 403. Google Scholar 10 : Does isoniazid reduce side effects of intravesical bacillus Calmette-Guérin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol1997; 157: 1246. Link, Google Scholar 11 : TNM classification of Malignant Tumors. In: . Edited by . New York: Wiley Liss1997: 107. Google Scholar 12 : Significance of bladder biopsies in Ta, T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol1999; 35: 267. Google Scholar 13 : Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol1992; 147: 596. Link, Google Scholar 14 : Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol1995; 27: 19. Google Scholar 15 : Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol1997; 158: 378. Link, Google Scholar 16 : A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol1996; 156: 1934. Link, Google Scholar 17 : The treated natural history of high risk superficial bladder cancer: fifteen year outcome. J Urol1997; 158: 62. Link, Google Scholar 18 : Tumour progression and survival in patients with T1 G3 bladder tumours: 15-year outcome. Br J Urol1997; 80: 762. Google Scholar From the Bosch Medicentrum, s’Hertogenbosch, University of Maastricht, Maastricht and Erasmus University Rotterdam, Rotterdam, The Netherlands, University of Modena, Modena, Italy, and European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byHendricksen K, Cornel E, de Reijke T, Arentsen H, Chawla S and Witjes J (2018) Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 187, NO. 4, (1195-1199), Online publication date: 1-Apr-2012.Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S and Bartoletti R (2018) Can Early Single Dose Instillation of Epirubicin Improve Bacillus Calmette-Guerin Efficacy in Patients With Nonmuscle Invasive High Risk Bladder Cancer? Results From a Prospective, Randomized, Double-Blind Controlled StudyJournal of Urology, VOL. 180, NO. 1, (110-115), Online publication date: 1-Jul-2008.Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L and Rischmann P (2018) The Effect of Ofloxacin on Bacillus Calmette-Guerin Induced Toxicity in Patients With Superficial Bladder Cancer: Results of a Randomized, Prospective, Double-Blind, Placebo Controlled, Multicenter StudyJournal of Urology, VOL. 176, NO. 3, (935-939), Online publication date: 1-Sep-2006.ARDELT P, WOOD C, CHEN L, MINTZ P, MOYA C, ARAP M, WRIGHT K, PASQUALINI R and ARAP W (2018) Targeting Urothelium: Ex Vivo Assay Standardization and Selection of Internalizing LigandsJournal of Urology, VOL. 169, NO. 4, (1535-1540), Online publication date: 1-Apr-2003.SYLVESTER R, van der MEIJDEN A and LAMM D (2018) Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, VOL. 168, NO. 5, (1964-1970), Online publication date: 1-Nov-2002.Soloway M, Sofer M and Vaidya A (2018) Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The BladderJournal of Urology, VOL. 167, NO. 4, (1573-1583), Online publication date: 1-Apr-2002.Durek C, Jurczok A, Werner H, Jocham D and Böhle A (2018) Optimal Treatment of Systemic Bacillus Calmette-Guerin Infection: Investigations in an Animal ModelJournal of Urology, VOL. 168, NO. 2, (826-831), Online publication date: 1-Aug-2002. Volume 166Issue 2August 2001Page: 476-481 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordscarcinomaepirubicinmycobacterium bovisisoniazidbladder neoplasmstransitional cellMetricsAuthor Information ADRIAN P.M. VAN DER MEIJDEN More articles by this author MAURIZIO BRAUSI More articles by this author VICTOR ZAMBON More articles by this author WIM KIRKELS More articles by this author CHRISTINE DE BALINCOURT More articles by this author RICHARD SYLVESTER More articles by this author MEMBERS OF THE EORTC GENITO-URINARY GROUP* Participants: A. van der Meijden, s’Hertogenbosch, C. Boeken-Kruger and W. Kirkels, Rotterdam, P. Karthaus and K. Kurth, Amsterdam, P. Vegt, Leiderdorp, J.-V. Zambon, Maastricht, The Netherlands; W. Oosterlinck, Gent, Belgium; J. Carballido, Madrid, Spain; P. Whelan, Leeds, R. Hall, Newcastle-upon-Tyne, D. Hanbury, Stevenage, United Kingdom; S. Ferretti, Carpi, A. Bono, Varese, G. Casetta, Torino, M. Brausi, Modena, Italy; F. Calais da Silva, Lisbon, Portugal; W. Hoeltl, Vienna, D. Mack, Salzburg, Austria; and Z. Kirkali, Izmir, Turkey. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2099982247 created "2016-06-24" @default.
• W2099982247 creator A5004584899 @default.
• W2099982247 creator A5005778011 @default.
• W2099982247 creator A5032443161 @default.
• W2099982247 creator A5049762337 @default.
• W2099982247 creator A5075711884 @default.
• W2099982247 creator A5081220576 @default.
• W2099982247 date "2001-08-01" @default.
• W2099982247 modified "2023-10-14" @default.
• W2099982247 title "INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL" @default.
• W2099982247 cites W1423791052 @default.
• W2099982247 cites W2008782229 @default.
• W2099982247 cites W2018664504 @default.
• W2099982247 cites W2051352978 @default.
• W2099982247 cites W2065098303 @default.
• W2099982247 cites W2081194991 @default.
• W2099982247 cites W2101974891 @default.
• W2099982247 cites W2108556628 @default.
• W2099982247 cites W2122606013 @default.
• W2099982247 cites W2126903040 @default.
• W2099982247 cites W2152206210 @default.
• W2099982247 cites W2333193688 @default.
• W2099982247 cites W2414877258 @default.
• W2099982247 cites W2417407414 @default.
• W2099982247 cites W4317523048 @default.
• W2099982247 doi "https://doi.org/10.1016/s0022-5347(05)65966-6" @default.
• W2099982247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11458050" @default.
• W2099982247 hasPublicationYear "2001" @default.
• W2099982247 type Work @default.
• W2099982247 sameAs 2099982247 @default.
• W2099982247 citedByCount "124" @default.
• W2099982247 countsByYear W20999822472012 @default.
• W2099982247 countsByYear W20999822472013 @default.
• W2099982247 countsByYear W20999822472014 @default.
• W2099982247 countsByYear W20999822472015 @default.
• W2099982247 countsByYear W20999822472016 @default.
• W2099982247 countsByYear W20999822472017 @default.
• W2099982247 countsByYear W20999822472018 @default.
• W2099982247 countsByYear W20999822472019 @default.
• W2099982247 countsByYear W20999822472020 @default.
• W2099982247 countsByYear W20999822472021 @default.
• W2099982247 countsByYear W20999822472022 @default.
• W2099982247 crossrefType "journal-article" @default.
• W2099982247 hasAuthorship W2099982247A5004584899 @default.
• W2099982247 hasAuthorship W2099982247A5005778011 @default.
• W2099982247 hasAuthorship W2099982247A5032443161 @default.
• W2099982247 hasAuthorship W2099982247A5049762337 @default.
• W2099982247 hasAuthorship W2099982247A5075711884 @default.
• W2099982247 hasAuthorship W2099982247A5081220576 @default.
• W2099982247 hasConcept C121608353 @default.
• W2099982247 hasConcept C126322002 @default.
• W2099982247 hasConcept C126894567 @default.
• W2099982247 hasConcept C142724271 @default.
• W2099982247 hasConcept C2776694085 @default.
• W2099982247 hasConcept C2776755627 @default.
• W2099982247 hasConcept C2776967927 @default.
• W2099982247 hasConcept C2777546739 @default.
• W2099982247 hasConcept C2778288313 @default.
• W2099982247 hasConcept C2779150676 @default.
• W2099982247 hasConcept C2780352672 @default.
• W2099982247 hasConcept C2780835546 @default.
• W2099982247 hasConcept C2781069245 @default.
• W2099982247 hasConcept C2910508445 @default.
• W2099982247 hasConcept C29456083 @default.
• W2099982247 hasConcept C71924100 @default.
• W2099982247 hasConcept C86803240 @default.
• W2099982247 hasConcept C89423630 @default.
• W2099982247 hasConceptScore W2099982247C121608353 @default.
• W2099982247 hasConceptScore W2099982247C126322002 @default.
• W2099982247 hasConceptScore W2099982247C126894567 @default.
• W2099982247 hasConceptScore W2099982247C142724271 @default.
• W2099982247 hasConceptScore W2099982247C2776694085 @default.
• W2099982247 hasConceptScore W2099982247C2776755627 @default.
• W2099982247 hasConceptScore W2099982247C2776967927 @default.
• W2099982247 hasConceptScore W2099982247C2777546739 @default.
• W2099982247 hasConceptScore W2099982247C2778288313 @default.
• W2099982247 hasConceptScore W2099982247C2779150676 @default.
• W2099982247 hasConceptScore W2099982247C2780352672 @default.
• W2099982247 hasConceptScore W2099982247C2780835546 @default.
• W2099982247 hasConceptScore W2099982247C2781069245 @default.
• W2099982247 hasConceptScore W2099982247C2910508445 @default.
• W2099982247 hasConceptScore W2099982247C29456083 @default.
• W2099982247 hasConceptScore W2099982247C71924100 @default.
• W2099982247 hasConceptScore W2099982247C86803240 @default.
• W2099982247 hasConceptScore W2099982247C89423630 @default.
• W2099982247 hasIssue "2" @default.
• W2099982247 hasLocation W20999822471 @default.
• W2099982247 hasOpenAccess W2099982247 @default.
• W2099982247 hasPrimaryLocation W20999822471 @default.
• W2099982247 hasRelatedWork W1786176614 @default.
• W2099982247 hasRelatedWork W2050606735 @default.
• W2099982247 hasRelatedWork W2063071428 @default.
• W2099982247 hasRelatedWork W2064952716 @default.
• W2099982247 hasRelatedWork W2074100121 @default.
• W2099982247 hasRelatedWork W2099982247 @default.
• W2099982247 hasRelatedWork W2161387704 @default.
• W2099982247 hasRelatedWork W2294123752 @default.

• next